tbuckley/cabot-search huggingface dataset:
Abstract 4840: Characterization of URST1 as a biomarker and therapeutic target for precision medicine of lung cancer
Authors: Atsushi Takano, Yohei Miyagi, Yataro Daigo
Journal: Cancer Research (2019)

Abstract This study aims to identify novel biomarkers and therapeutic targets for lung cancer. We initially screened genes that overexpressed in the majority of lung cancers by using our original gene expression profile database. During this process, we identified up-regulated in solid tumor 1 (URST1) as a candidate. Immunohistochemical staining showed that URST1 was expressed in 231 (64.5%) of 358 non-small cell lung cancer (NSCLC) that had undergone curative surgery. Strong URST1 expression was associated with poor prognosis for NSCLC patients (P = 0.0003 by log-rank test). In addition, multivariate analysis showed that strong URST1 expression was an independent prognostic factor for NSCLC patients. Reduction of URST1 expression by siRNA or treatment with selective URST1 inhibitor significantly suppressed cancer cell growth partly through cell cycle arrest at G2/M phase and mitotic cell death as detected by flow cytometric analysis and live cell imaging. Our findings suggest that URST1 could be a potential biomarker and therapeutic target for developing precision medicine of lung cancer. Note: This abstract was not presented at the meeting. Citation Format: Atsushi Takano, Yohei Miyagi, Yataro Daigo. Characterization of URST1 as a biomarker and therapeutic target for precision medicine of lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4840.
Apo E Effects on Blood Cholesterol Are Independent of Growth and Maturation in Adolescent Girls: Project HeartBeat!
Authors: Shifan - Dai, Janet E. Fulton, Jo Anne Grunbaum, Eric Boerwinkle, Darwin R. Labarthe
Journal: Circulation (2001)

P15 Apolipoprotein E polymorphism (apo E) is a genetic determinant of lipid and lipoprotein levels and subsequent risk for CHD. We have previously demonstrated that girls with ε3/3 or ε3/4 genotypes had both higher total (TC) and LDL-cholesterol (LDL-C) throughout ages 8 to 18 compared with those with the ε2/3 genotype. The current analysis further explored potential confounding or interaction effects of physical growth, body composition, sexual maturation, and endocrine function with apo E. In Project HeartBeat!, a mixed longitudinal study of CVD risk factor development in children, apo E genotyping was performed among 331 girls aged 8, 11, and 14 years at baseline. Plasma lipid concentrations, weight, height, body mass index (BMI), skinfolds, fat free mass (FFM), percent body fat (%BF), Tanner stage (pubic hair, PH), and endocrine function (estradiol, EST) were determined by standard methods 3 times a year for up to 4 years. Analyses were restricted to 247 Caucasian girls. The numbers of measurements used ranged from 1090 to 1960 according to the combination of variables in different multilevel linear models. FFM, BMI, %BF, PH, and EST each showed a significant effect on TC and LDL-C whether tested alone or included in models containing age (age, age 2 , and age 3 ), apo E (ε2/3, ε3/3, and ε3/4), and age-apo E interaction terms. Age, apo E, and age-apo E interaction terms were strong, independent determinants of TC and LDL-C. Except for a ε3/4-by-%BF interaction, all 2-way interaction effects between apo E and FFM, BMI, %BF, PH, and EST were not significant in either TC or LDL-C models (P&gt;.05). We conclude that the apo E effects on age-related serial changes in TC and LDL-C are independent of physical growth, body composition, sexual maturation, and estradiol level in normal adolescent girls. Girls with ε3/3 or ε3/4 genotypes may be at higher risk for elevated TC and LDL-C later in life. These genotypes were found in 85% of the study population and may be important to identify in intervention studies or in clinical practice to evaluate responsiveness to lipid-lowering therapy.
Laboratory Diagnosis of Polycythemia and Anemia
Authors: Thomas Hale Ham, William B. Castle, Frank H. Gardner, Geneva A. Daland
Journal: New England Journal of Medicine (1950)

1. Diagnostic Problem in Polycythemia and Anemia Diagnosis of Polycythemia The presence of polycythemia may be suspected from the appearance of the patient or detected readily by determination of the hemoglobin or hematocrit of peripheral blood. The physician will usually be able to recognize, from the history and physical examination, whether polycythemia results from loss of plasma or from hemoconcentration, or is related to a condition producing arterial anoxia (Table 1). If there is a normal arterial oxygen saturation in the presence of polycythemia, the clinical problem is more complex, requiring the recognition of such conditions as an early phase . . .
Nits or not? Pseudonits--simple office diagnosis
Authors: M. J. Scott
Journal: JAMA (1980)

Some hair anomalies are often misdiagnosed as nits. Simple office procedures and techniques can differentiate pseudonits from nits. Knowledge of these basic disorders and procedures will eliminate any misdiagnosis of nits and thereby prevent any unnecessary treatment, anxiety, or embarrassment. (<i>JAMA</i>243:2325-2326, 1980)
ERYTHEMA NUCHAE.
Authors: F. RAY BETTLEY
Journal: British Journal of Dermatology (1940)

Journal Article ERYTHEMA NUCHAE. Get access F. RAY BETTLEY, M.D., M.R.C.P. F. RAY BETTLEY, M.D., M.R.C.P. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 52, Issue 12, 1 December 1940, Pages 363–370, https://doi.org/10.1111/j.1365-2133.1940.tb09898.x Published: 01 December 1940
Evidence mounts that other infections may trigger AIDS virus replication
Authors: C. A. Raymond
Journal: JAMA (1987)

CAN T-CELL-MEDIATED responses to other bacterial, viral, or protozoal infections trigger multiplication of a heretofore dormant human immunodeficiency virus (HIV) infection? A just-announced finding—identification of a protein unique to activated T cells that greatly enhances the in vitro expression of HIV (<i>Nature</i>1987;326:711-713)— lends credence to this concept. At least one scientist believes that the data suggest a new approach to intervention, although—as in other antiviral research —many, perhaps insurmountable, hurdles remain. At the very least, the report supports the merits of having persons who are HIV-positive reduce their exposure, insofar as possible, to other infections. Gary Nabel, MD, PhD, a molecular biologist at the Whitehead Institute for Biomedical Research in Cambridge, Mass, reports that the study involved two steps. First, based on previous studies that showed that HIV established itself better in activated rather than resting T cells, they tried to identify a factor unique to such cells. Nabel
Gut hormones/receptors
Authors: A Arienzo, L Cimino, G Scarpa, F Manguso, P Cocchia, G Budillon, G Mazzacca, O Gilja, A Smievoll, N Thune, K Matre, T Hausken
Journal: Gut (1994)

3rd UEGWOslo 1994 RNA positive, were negative by anti-Cl 00-3, but all were positive by anti-HCV 11.One hundred thirty four (93.7%) patients proven anti-HCV 11 positive, were all positive by HCV-RNA.But 9 (6.3%) patients who were proven HCV-RNA negative, were positive by anti-HCV 11.We determined the genotype of these 9 patients and found that 3 patients had type ll, one patient had type IV and the remaining 5 were again negative in this test.Conclusions: (1) Anti-HCV II was more sensitive and specific than the anti- C100-3, and was available for screening of chronic HCV infection.Detecting HCV-RNA was not practically useful in screening chronic infection. (2)In a small number of patients with genotype IlIl or IV, HCV-RNA could not be detected by RT-PCR using primers for the 5' non-coding region.If chronic hepatitis C patients are HCV-RNA negative but anti-HCV 11 positive, we can assume that the genotype of some of them are IlIl or IV 1058
Lead, Blood Pressure, and Cardiovascular Disease in Men and Women
Authors: Joel Schwartz
Journal: Environmental Health Perspectives (1991)

Lead has been shown to be associated with elevated blood pressure in males in the NHANES II survey and in numerous other studies. This study confirms the association in males aged 20 to 74 and documents a significant, although weaker, association in females as well. Prospective cardiovascular disease studies such as the Framingham study indicate that increases in blood pressure should be associated with increased risk of cardiovascular disease. Using electrocardiogram data from NHANES II, this study confirms the expected association of lead with left ventricular hypertrophy (p less than 0.01). Such an association with permanent cardiovascular changes adds weight to the blood pressure findings. The logistic risk coefficients from the Framingham study can be combined with the study's association between lead and blood pressure to examine its implication for more serious outcomes. The results suggest that a halving of the population mean blood lead level would reduce myocardial infarctions by approximately 24,000 events per year and incidence of all cardiovascular disease by over 100,000. These numbers suggest a small attributable risk compared to the vast incidence of cardiovascular disease in the U.S., but a large attributable risk compared to most environmental toxins. Several biological mechanisms have been identified, with different implications for the use of bone lead as an exposure measure.
Surgeon General's Conference on Agriculture
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.
Authors: S. Vincent Rajkumar, Suzanne Hayman, Martha Q. Lacy, Angela Dispenzieri, Susan M. Geyer, Brian Kabat, Steven R. Zeldenrust, Shaji Kumar, Philip R. Greipp, Rafael Fonseca, John A. Lust, Stephen J. Russell, Robert A. Kyle, Thomas E. Witzig, Morie A. Gertz
Journal: Blood (2005)
Infectious Diseases
Authors: Harry B. Greenberg
Journal: JAMA (1974)

Fitting the antibiotic to the infecting organism occupies most of the attention of the eight contributors to<i>Infectious Diseases</i>. First they discuss the penicillins (they prefer to give only one type of penicillin at a time); then they take up most of the other commercially available antimicrobial drugs. They provide alternative treatments for drug-allergic patients and special dosage schedules for the patient with a damaged liver or kidneys. Whenever practicable, they treat each patient's infection with a single, preferably bactericidal, antibiotic, and combine antibiotics only in special cases such as enterococcal or abacteremic endocarditis (they give penicillin and streptomycin for at least six weeks); for<i>Pseudomonas</i>septicemia, they recommend gentamicin and carbenicillin; for undefined sepsis, they start treatment with gentamicin and ampicillin or oxacillin; and for advanced tuberculosis, they initiate treatment with isoniazid, ethambutol, and streptomycin. Their discussions also include the reports of persisting treponemas in treated patients with late
Monitoring Human Lymphocytic DNA-Protein Cross-Links as Biomarkers of Biologically Active Doses of Chromate
Authors: Max Costa, Anatoly Zhitkovich, Paolo Toniolo, Emanuela Taioli, Todor Popov, Annekatrin Lukanova
Journal: Environmental Health Perspectives (1996)

A simple and sensitive assay for DNA-protein cross-links has been used as a biomarker of chromate exposure and early carcinogenic effects.Pilot studies of DNA-protein cross-links in peripheral blood lymphocytes have been conducted with individuals who had higher exposure to chromate, including welders, and with individuals who had lower levels of exposure such as residents living in a chromium-contaminated area in Jersey City, New Jersey.Studies were also conducted in two Bulgarian cities (Jambol and Burgas) with different levels of air pollution and Cr(VI) exposure and in chrome platers in Bulgaria who had high exposure to chromate.DNA- protein cross-links in U.S. welders and in individuals living in Hudson County, New Jersey around chromium-contaminated areas were significantly higher compared to matched controls.Although blood and urinary levels of chromium were not extensively studied in these populations, we were able to obtain these measurements in the Bulgarian population.Chromium levels in red blood cells of controls living in Burgas were in the order of 1 to 2 ppb chromium, and these individuals had the lowest levels of DNA-protein cross-links.However, the chromium levels in Jambol ranged from about 2 to 7 ppb in red blood cells of city residents to about 22 ppb in chrome platers.DNA-protein cross-links were saturated at about 7 to 8 ppb chromium in the red blood cells, and cross-links correlated well only with chromium levels in red blood cells.Urinary chromium levels did not correlate well with either DNA-protein cross-links or chromium levels in with red blood cells.
The 1936 Year Book of Neurology, Psychiatry and Endocrinology. Edited by<i>Hans H. Reese, M. D., Harry A. Paskind, M. D., Ph. D., and Elmer L. Sevringhaus, M.D.</i>(Chicago: The Year Book Publishers, 1937.)
Authors: C. B. F.
Journal: American Journal of Psychiatry (1937)
Viral Hepatitis Statistics Questioned
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ELEVATORS IN SCHOOLS AND HEART DISEASE
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neue klinische Gesichtspunkte zur Lehre vom Asthma cardiale,
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NO COMMERCIALISM IN SWEDEN.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights from this issue
Journal: Thorax (2016)

The term "fat happy wheezer" was formerly used to describe plump, pre-school children who had an episode of wheezing but who generally did well.The term has fallen into disuse most parents don't like the term "fat".On page 1091 of this issue Maja Popovic, and colleagues examine the relationship between infant size, weight velocity and tempo (age at peak weight velocity) and wheezing between 6 months and 18 years of age.They find that infant size and weight velocity are related to the risk of wheezing but that tempo is not.More work is needed to explore the mechanism by which faster growth and larger size might produce a "fat happy wheezer".
Letter: Consultant contract.
Journal: BMJ (1974)

outlining progress of the Owen Working Party on consultant con- tracts.We are pleased that there appears to be an acceptance that all consultants, whether opting for private practice or not, have a right to a 10-session contract if they so wish.This we feel is only just, but of course im- plies a 10-session com,mitment to the National Health Service for all concerned.We note with concern, however, the follow- ing sentence relating to those who do not opt for private practice: "[The Government] is not, however, prepared to depart from the concept of devoting some element of addi- tional remuneration to recognize 'an intangible advantage,' as opposed to identifi- able commitment in either work or standby."This would suggest to us that this not un- reasonable proposal by the Government is being opposed by our representatives, and we wonder on what authority they are doing so.
Scrabble
Authors: Dawn McGuire
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Medicine
Authors: Antoni Trilla
Journal: JAMA (1995)

<h3>To the Editor.</h3> —In an excellent article published recently in<i>JAMA</i>, Dr Leape<sup>1</sup>discusses the mechanisms and some models of medical errors. In his initial statement, however, a historical error is introduced. Florence Nightingale must take credit for many important contributions to the progress of medicine and nursing, but certainly not for being the original author of the dictum, "first, do no harm." Since the time of Hippocrates (circa 500 BC), the principle of "primum non nocere" ("the first thing [is] to do no harm" or "above all, do no harm") has been quoted by medical writers with respect and considered "medicine's most cherished principle."<sup>2</sup>It has been taught this way to every medical and nursing student throughout the world and through the years. However, even the real meaning and logic of this principle has been questioned recently in an excellent review by Brewin,<sup>3</sup>suggesting that it